Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
04:31pm, Tuesday, 21'st Apr 2026
COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Con
Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND
03:24am, Tuesday, 21'st Apr 2026
Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,579 sh
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
08:00am, Monday, 20'th Apr 2026
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
12:00pm, Wednesday, 08'th Apr 2026
- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq
- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
04:01pm, Monday, 06'th Apr 2026
- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses
Braun Stacey Associates Inc. Buys 25,148 Shares of Ascendis Pharma A/S $ASND
04:35am, Sunday, 05'th Apr 2026
Braun Stacey Associates Inc. grew its stake in Ascendis Pharma A/S (NASDAQ: ASND) by 26.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission
Allspring Global Investments Holdings LLC Has $40.02 Million Stock Position in Ascendis Pharma A/S $ASND
03:09am, Friday, 03'rd Apr 2026
Allspring Global Investments Holdings LLC lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ: ASND) by 2.1% during the undefined quarter, according to the company in its most recent disclo
Ascendis Pharma A/S (NASDAQ:ASND) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?
04:33am, Wednesday, 01'st Apr 2026
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s share price passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $227.04 and traded as high
- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar at Week 52 to daily somatropin-treated children - TransCon hGH showed a safety and tolerability p
Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND
03:36am, Tuesday, 17'th Mar 2026
Bamco Inc. NY bought a new stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange C
COPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated wi
Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND
03:30am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ: ASND) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commis
Invesco Main Street Mid Cap Fund Q4 2025 Portfolio Activity
12:49pm, Thursday, 12'th Mar 2026
We maintain our valuation discipline and our focus on companies with competitive advantages and skilled management teams that we believe are executing better than their peers. We initiated a position
Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND
04:02am, Thursday, 12'th Mar 2026
Barometer Capital Management Inc. increased its position in Ascendis Pharma A/S (NASDAQ: ASND) by 288.8% during the third quarter, according to the company in its most recent 13F filing with the Secur
